References
- Jacobsen SM, Shirtliff ME. Proteus mirabilis biofilms and catheter-associated urinary tract infections. Virulence. 2011; 2:460-5.2192168710.4161/viru.2.5.17783
- Jombo GTA, Emanghe UE, Amefule EN, Damen JG. Nosocomial and community acquired uropathogenic isolates of Proteus mirabilis and antimicrobial susceptibility profiles at a university hospital in Sub–Saharan Africa. Asian Pac J Trop Dis. 2012; 1: 7-11.
- Nucleo E, Fugazza G, Migliavacca R, Spalla M, Comelli M, Pagani L, et al. Differences in biofilm formation and aggregative adherence between β-lactam susceptible and β-lactamases producing P. mirabilis clinical isolates. New Microbiol. 2010; 33: 37-45.20402412
- Tumbarello M, Trecarichi EM, Fiori B, Losito AR, D’Inzeo T, Campana L, et al. Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother. 2012; 56:3224-31.2245097910.1128/AAC.05966-11
- Borghi L, Nouvenne A, Meschi T. Nephrolithiasis and urinary tract infections: ‘the chicken or the egg’ dilemma? Nephrol Dial Transplant. 2012; 27:3982-4.10.1093/ndt/gfs39523144068
- Chen C-Y, Chen Y-H, Lu P-L, Lin W-R, Chen T-C, Lin C-Y. Proteus mirabilis urinary tract infection and bacteremia: Risk factors, clinical presentation, and outcomes. J Microbiol Immunol Infect. 2012; 45: 228-36.10.1016/j.jmii.2011.11.00722572004
- Eyoh AB, Toukam M, Atashili J, Fokunang C, Gonsu H, Lyonga EE, et al. Relationship between multiple drug resistance and biofilm formation in Staphylococcus aureus isolated from medical and non-medical personnel in Yaounde, Cameroon. Pan Afr Med J. 2014; 17:186. doi:10.11604/pamj.2014.17.186.236325396012
- Rao RS, Karthika RU, Singh SP, Shashikala P, Kanungo R, Jayachandran S, et al. Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii. Indian J Med Microbiol. 2008; 26:333-7.10.4103/0255-0857.4356618974485
- Subramanian P, Shanmugam N, Sivaraman U, Kumar S, Selvaraj S. Antibiotic resistance pattern of biofilmforming uropathogens isolated from catheterised patients in Pondicherry, India. Australas Med J. 2012; 5:344-8.10.4066/AMJ.2012.1193
- Holt JG, Krieg NR, Sneath PHA, Staley JT, Williams ST, editors. Bergey’s manual of determinative bacteriology. 9th ed. Baltimore: Williams & Wilkins; 1994.
- O’Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011; 30:2437.
- Marcus RJ, Post JC, Stoodley P, Hall-Stoodley L, McGill RL, Sureshkumar KK, et al. Biofilms in nephrology. Expert Opin Biol Ther. 2008; 8:1159-66.10.1517/14712598.8.8.115918613767
- Saito R, Okugawa S, Kumita W, Sato K, Chida T, Okamura N, et al. Clinical epidemiology of ciprofloxacin resistant P. mirabilis isolated from urine samples of hospitalised patients. Clin Microbiol Infect. 2007; 13: 1204-6.1785034010.1111/j.1469-0691.2007.01826.x
- Broomfield RJ, Morgan SD, Khan A, Stickler DJ. Crystalline bacterial biofilm formation on urinary catheters by urease-producing urinary tract pathogens: a simple method of control. J Med Microbiol. 2009; 58:1367-75.1955637310.1099/jmm.0.012419-0
- Kurihara Y, Hitomi S, Oishi T, Kondo T, Ebihara T, Funayama Y, et al. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis. J Infect Chemother. 2013; 19:799-805.2337145310.1007/s10156-013-0563-3
- Feglo PK, Gbedema SY, Quay SNA, Adu-Sarkodie Y, Opoku-Okrah C. Occurrence, species distribution and antibiotic resistance of Proteus isolates: A case study at the Komfo Anokye Teaching Hospital (KATH) in Ghana. Int J Pharm Sci Res. 2010; 1:347-52.
- Feneley RC, Kunin CM, Stickler DJ. An indwelling urinary catheter for the 21st century. BJU Int. 2012; 109:1746-9.2209402310.1111/j.1464-410X.2011.10753.x
- Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol. 2003; 57:677-701.10.1146/annurev.micro.57.030502.09072014527295
- Sas DJ, Hulsey TC, Shatat IF, Orak JK. Increasing incidence of kidney stones in children evaluated in the emergency department. J Pediatr. 2010; 157:132-7.10.1016/j.jpeds.2010.02.00420362300
- Stock I. Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains. J Chemother. 2003; 15:12-26.10.1179/joc.2003.15.1.12
- Prywer J, Sadowski RR, Torzewska A. Aggregation of struvite, carbonate apatite, and Proteus mirabilis as a key factor of infectious urinary stone formation. Cryst Growth Des. 2015; 15:1446-51.10.1021/cg5018032
- Adamus-Bialek W, Zajac E, Parniewski P and Kaca W. Comparison of antibiotic resistance patterns in collections of Escherichia coli and Proteus mirabilis uropathogenic strains. Mol Biol Rep. 2013; 40: 3429-35.2328374110.1007/s11033-012-2420-3
- Edlin RS, Shapiro DJ, Hersh AL, Copp HL. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol. 2013; 190:222-7.2336972010.1016/j.juro.2013.01.069
- Sohn KM, Kang C-I, Joo EJ, Ha YE, Chung DR, Peck KR, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia. Korean J Intern Med. 2011; 26:89-93.10.3904/kjim.2011.26.1.8921437168
- Fernandez L, Breidenstein EB, Hancock RE. Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat. 2011; 14:1-21.10.1016/j.drup.2011.01.00121288762
- Aragn LM, Mirelis B, Mir E, Mata C, G mez L, Rivera A, et al. Increase in b-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type β-lactamases. J Antimicrob Chemother. 2008; 61: 1029-32.1829209610.1093/jac/dkn056